Equities analysts expect Hologic, Inc. (NASDAQ:HOLX) to post $798.96 million in sales for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided estimates for Hologic’s earnings, with the highest sales estimate coming in at $803.00 million and the lowest estimate coming in at $790.83 million. Hologic posted sales of $717.40 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 11.4%. The business is scheduled to report its next earnings results after the market closes on Wednesday, August 2nd.

According to Zacks, analysts expect that Hologic will report full year sales of $798.96 million for the current financial year, with estimates ranging from $3.05 billion to $3.08 billion. For the next financial year, analysts expect that the company will post sales of $3.36 billion per share, with estimates ranging from $3.32 billion to $3.43 billion. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Hologic.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, May 10th. The medical equipment provider reported $0.50 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.46 by $0.04. The company had revenue of $715.40 million for the quarter, compared to analysts’ expectations of $685.24 million. Hologic had a return on equity of 25.26% and a net margin of 27.31%. The firm’s revenue for the quarter was up 3.2% on a year-over-year basis. During the same period in the prior year, the firm earned $0.47 earnings per share.

A number of brokerages recently issued reports on HOLX. Stifel Nicolaus raised their price target on Hologic from $45.00 to $48.00 and gave the stock a “buy” rating in a research note on Thursday, May 11th. Jefferies Group LLC reaffirmed a “buy” rating and set a $49.00 target price on shares of Hologic in a research report on Wednesday, June 28th. Bank of America Corporation reaffirmed a “neutral” rating and set a $48.00 target price (up from $44.00) on shares of Hologic in a research report on Friday, July 21st. Canaccord Genuity reaffirmed a “buy” rating and set a $53.00 target price on shares of Hologic in a research report on Tuesday, May 9th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $51.00 target price on shares of Hologic in a research report on Friday, July 14th. One research analyst has rated the stock with a sell rating, four have given a hold rating and ten have given a buy rating to the stock. Hologic presently has a consensus rating of “Buy” and a consensus target price of $47.79.

COPYRIGHT VIOLATION WARNING: This story was originally published by American Banking News and is the property of of American Banking News. If you are reading this story on another publication, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The correct version of this story can be read at https://www.americanbankingnews.com/2017/07/26/798-96-million-in-sales-expected-for-hologic-inc-nasdaqholx-this-quarter.html.

In other news, Director Lawrence M. Levy sold 10,203 shares of the business’s stock in a transaction on Wednesday, May 3rd. The stock was sold at an average price of $45.00, for a total value of $459,135.00. Following the completion of the transaction, the director now directly owns 38,832 shares of the company’s stock, valued at approximately $1,747,440. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Karleen Marie Oberton sold 4,704 shares of the business’s stock in a transaction on Monday, July 17th. The stock was sold at an average price of $45.19, for a total value of $212,573.76. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 73,765 shares of company stock valued at $3,261,148. 0.79% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HOLX. Victory Capital Management Inc. raised its position in Hologic by 418.5% in the first quarter. Victory Capital Management Inc. now owns 4,050,824 shares of the medical equipment provider’s stock valued at $172,363,000 after buying an additional 3,269,503 shares during the last quarter. American Century Companies Inc. raised its position in Hologic by 229.4% in the first quarter. American Century Companies Inc. now owns 3,164,928 shares of the medical equipment provider’s stock valued at $134,668,000 after buying an additional 2,204,085 shares during the last quarter. Bank of Montreal Can raised its position in Hologic by 67.8% in the first quarter. Bank of Montreal Can now owns 3,206,769 shares of the medical equipment provider’s stock valued at $136,448,000 after buying an additional 1,295,885 shares during the last quarter. UBS Asset Management Americas Inc. raised its position in Hologic by 123.2% in the fourth quarter. UBS Asset Management Americas Inc. now owns 1,446,445 shares of the medical equipment provider’s stock valued at $58,032,000 after buying an additional 798,541 shares during the last quarter. Finally, Russell Investments Group Ltd. raised its position in Hologic by 229.7% in the second quarter. Russell Investments Group Ltd. now owns 1,059,586 shares of the medical equipment provider’s stock valued at $48,100,000 after buying an additional 738,215 shares during the last quarter. 94.09% of the stock is owned by hedge funds and other institutional investors.

Shares of Hologic (NASDAQ:HOLX) opened at 45.09 on Wednesday. The company has a 50-day moving average price of $45.10 and a 200 day moving average price of $42.80. The stock has a market capitalization of $12.63 billion, a PE ratio of 16.17 and a beta of 0.91. Hologic has a 52 week low of $35.15 and a 52 week high of $46.80.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Get a free copy of the Zacks research report on Hologic (HOLX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.